National Health Service (NHS) Research This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.

EE212 Understanding Service Use for Melanoma in the UK National Health Service: An Expert Elicitation Exercise Using a New Method for Eliciting Proportions
When empirical evidence is not available, decision models often require expert estimates of input parameters. Beta distributions commonly represent uncertainty for proportions of interest. Published methods for eliciting proportions ask experts to characterise the density of the uncertainty distribution in various ways. Estimating treatment costs for melanoma requires an understanding of the proportions of people receiving each intervention. We aimed to elicit proportions receiving each intervention in the care pathway for melanoma. (Source: Value in Health)
Source: Value in Health - December 1, 2023 Category: International Medicine & Public Health Authors: R. Hainsworth, M. Eden, K. Payne, G. Rogers Source Type: research

EE420 Cost-Effectiveness of Empagliflozin in Chronic Kidney Disease (CKD) Management in the UK
This study uses the Chronic Kidney Disease Progression Model (CKD-PM) to demonstrate the cost-effectiveness of empagliflozin for the treatment of CKD to the National Institute for Health and Care Excellence (NICE), from the perspective of the UK National Health Service (NHS) and personal social services (PSS). (Source: Value in Health)
Source: Value in Health - December 1, 2023 Category: International Medicine & Public Health Authors: M. Ramos, L. Gerlier, A. Uster, A.R. Aguirre, L. Muttram, A.H. Frankel, M. Lamotte Source Type: research

EE359 Cost-Effectiveness of Pembrolizumab + Chemotherapy Versus Cetuximab-Containing Regimens ‘Extreme’ and ‘TPEx’, for R/M SCCHN Patients with a CPS between 1 and 19, in Italy
In this study, we present cost-effectiveness (CE) outcomes of pembrolizumab + chemotherapy (P+CT) for patients with recurrent/metastatic squamous cell carcinoma of the head and neck (R/M SCCHN) and a combined positive score (CPS) of 1-19, compared with cetuximab-containing regimens (CCRs: ‘EXTREME’, cetuximab/5-FU/cis-, or carboplatin and ‘TPEx’, cetuximab/docetaxel/cis-, or carboplatin). The CE analysis was developed from an Italian National Health Service perspective. (Source: Value in Health)
Source: Value in Health - December 1, 2023 Category: International Medicine & Public Health Authors: P. Ivanyi, A. Bullement, A. Ciccarone, M. Schlichting, J. Naik, G.L. Colombo, A. Gandola, C.P. Pescott Source Type: research

EE308 Cost-Utility Analysis of Universal Neonatal Screening for Critical Congenital Heart Disease Based on Pulse Oximetry in Spain
To analyze the cost-utility and estimate the budget impact of universal neonatal screening for critical congenital heart defects (CCHD) based on pulse oximetry (PO) compared with no screening in the context of the Spanish National Health Service (SNHS). (Source: Value in Health)
Source: Value in Health - December 1, 2023 Category: International Medicine & Public Health Authors: I. Imaz-Iglesia, A.I. Hijas-G ómez, J. Rodríguez-Arbáizar, A. Martínez-Portillo, C. Asensio, E. García Carpintero, C. Saborido, M. Carmona, J.C. Bayón, F. Gutiérrez-Larraya, M. Sánchez-Luna Source Type: research

EE540 Cost-Effectiveness of Brexucabtagene Autoleucel for the Treatment of Relapsed/Refractory B-Cell Acute Lymphoblastic Leukemia in Patients Aged 26 Years or Older in the United Kingdom
To estimate the cost-effectiveness of brexucabtagene autoleucel (BREXU-CEL) versus blinatumomab (BLIN), inotuzumab ozogamicin (INO), and salvage chemotherapy (CHEMO) for patients aged 26 years or older with relapsed/refractory B-cell acute lymphoblastic leukemia (R/R B-ALL) from a United Kingdom (UK) National Health Service and Personal Social Services perspective. (Source: Value in Health)
Source: Value in Health - December 1, 2023 Category: International Medicine & Public Health Authors: T. Spousta, C. Feng, F. van Hees, S. Wade, B. Doble Source Type: research

EE591 Impact of Flu Vaccine Shortage on the National Health Service (NHS) in England and Wales
This study assesses the clinical and financial impact of influenza vaccine shortage on the NHS and workforce productivity. (Source: Value in Health)
Source: Value in Health - December 1, 2023 Category: International Medicine & Public Health Authors: F. Amin, H. Lister, T. Poletti, G. Carins, G. Olivera Source Type: research

EE658 Cost-Consequence of Cladribine Tablets for the Treatment of Highly-Active Relapsing-Remitting Multiple Sclerosis (RRMS) in the UK
Relapsing-remitting multiple sclerosis (RRMS) is a chronic autoimmune disorder characterized by periods of symptom flare-ups, followed by periods of disease remission. The aim of this study was to develop an economic model to determine the cost-consequence of cladribine tablets (CladT) compared to other disease modifying therapies (DMTs) used for treating highly-active RRMS (HA-RRMS) from a UK National Health Service (NHS) perspective. (Source: Value in Health)
Source: Value in Health - December 1, 2023 Category: International Medicine & Public Health Authors: B. Miller, M. Russel-Szymczyk, I.S. Jensen, A. Shah, S.T. Alexopoulos, A. Herbert, T. McLean, N. Tundia Source Type: research

EE715 Faricimab Vs. Standard of Care in Patients with Neovascular Age-Related Macular Degeneration and Diabetic Macular Edema: A Cost-Utility Analysis in Italy
To assess the cost-utility of faricimab vs Standard of Care (SoC) in patients with neovascular Age-Related Macular Degeneration (nAMD) and Diabetic Macular Edema (DME), from both the perspective of the Italian National Health Service (SSN) and Society. (Source: Value in Health)
Source: Value in Health - December 1, 2023 Category: International Medicine & Public Health Authors: G. Ghetti, C. Porta, A. Fasci Source Type: research

EE756 Real World Evidence (RWE) Evaluation of Cost Savings through Continuous Vital Sign Monitoring in the Medical-Surgical Ward: A National Health Service (NHS) Experience
This study used RWE from the Chelsea and Westminster Hospital NHS Foundation Trust (CWFT) to estimate the cost-savings from continuous vital sign monitoring in NHS medical-surgical wards ( “wards”). (Source: Value in Health)
Source: Value in Health - December 1, 2023 Category: International Medicine & Public Health Authors: S.N. Khan, M. Luchetti, J.W. Beard Source Type: research

EE731 Estimating the Economic Impact of Enabling the Digital Transfer of Patients ’ Prescription Information in the English National Health Service
This study aimed to estimate the number and burden of medication errors associated with prescription information transfer within the National Health Service (NHS) in England and the impact of implementing an interoperable prescription information system (a single digital prescribing record shared across NHS settings) in reducing these errors. (Source: Value in Health)
Source: Value in Health - December 1, 2023 Category: International Medicine & Public Health Authors: R. Elliott, E. Camacho, S. Gavan, R. Keers, A. Chuter Source Type: research

EPH137 Healthcare Resource Consumption and Direct Costs of Patients Newly Diagnosed with Acute Myeloid Leukemia from a Large Italian Administrative Database
Assess the resource consumption and direct costs of the healthcare reimbursed by the Italian National Health Service (INHS) for patients newly diagnosed with acute myeloid leukemia (AML). (Source: Value in Health)
Source: Value in Health - December 1, 2023 Category: International Medicine & Public Health Authors: I. Dell'Anno, G. Ronconi, L. Dondi, L. Dondi, S. Calabria, C. Piccinni, A. Pedrini, I. Esposito, A. Addesi, A.P. Maggioni, N. Martini Source Type: research

EPH200 Healthcare Resource Consumption of Patients with Chronic Obstructive Pulmonary Disease Treated with Triple and Dual Therapy and Experiencing an Acute Exacerbation
Assess the healthcare resource consumption of patients with chronic obstructive pulmonary disease (COPD) treated with triple (TT) and dual (DT) therapy following an acute exacerbation (AECOPD), from the Italian National Health Service (INHS) ’s perspective. (Source: Value in Health)
Source: Value in Health - December 1, 2023 Category: International Medicine & Public Health Authors: S. Calabria, G. Ronconi, L. Dondi, L. Dondi, C. Piccinni, I. Dell'Anno, A. Pedrini, I. Esposito, O. Brignoli, G.W. Canonica, M. Carone, F. Di Marco, C. Micheletto, C. Vancheri, N. Martini Source Type: research

EPH257 Healthcare Resource Consumptions of Patients with Atopic Dermatitis through Italian Administrative Healthcare Data
To assess the healthcare resource consumption of adults before and after dupilumab treatment for atopic dermatitis (AD), from the perspective of the Italian National Health Service (INHS). (Source: Value in Health)
Source: Value in Health - December 1, 2023 Category: International Medicine & Public Health Authors: S. Calabria, G. Ronconi, L. Dondi, L. Dondi, I. Dell'Anno, I. Esposito, M. Scattareggia, P. Rogliani, M. Trimarchi, L. Naldi, N. Martini Source Type: research

PT8 Five-Year Healthcare Resource Consumption and Direct Costs of Women with a New Diagnosis of Hr+/HER2- Breast Cancer Primary or Advanced: Analysis of a Large Italian Administrative Database
Assess the healthcare resource consumption and direct costs by the Italian National Health Service (INHS) for women newly diagnosed with HR+/HER2- breast cancer (BC), by absence/presence of lymphnode (LNM)/distant metastases (DM). (Source: Value in Health)
Source: Value in Health - December 1, 2023 Category: International Medicine & Public Health Authors: I. Dell'Anno, G. Ronconi, L. Dondi, L. Dondi, S. Calabria, C. Piccinni, I. Esposito, A. Addesi, A. Pedrini, A.P. Maggioni, N. Martini Source Type: research

HSD76 Assessing the Carbon Intensity Profile of an Immunization Program Against RSV in Infants in the United Kingdom to Show the Reduction in Emissions Versus Standard of Care
This study estimates the impact on carbon emissions generated within the direct patient care pathway from a new monoclonal antibody immunization, nirsevimab, against RSV. (Source: Value in Health)
Source: Value in Health - December 1, 2023 Category: International Medicine & Public Health Authors: R. Hudson, T. Rigoine de Fougerolles, F. Leadley, M. Chetty, P. de la Tour Source Type: research